Atezolizumab: observed

113 studies: patients on it are followed, or it is given outside a trial. Page 1 of 2. Open to participants first (49), then studies with results posted, then the rest; newest registration first within each.

• Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07904494Report a problem
• Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in ColombiaRecruitingNCT07856212Report a problem
• Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)Not yet recruitingNCT07824765Report a problem
• Real-world Insight Into Systemic Therapies for HCC: Single-center StudyRecruitingNCT07814014Report a problem
• Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCCNot yet recruitingNCT07786792Report a problem
• Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular CarcinomaRecruitingNCT07734857Report a problem
• ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)Not yet recruitingNCT07661251Report a problem
• Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular CarcinomaRecruitingNCT07610551Report a problem
• Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular CarcinomaRecruitingNCT07495735Report a problem
• NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line TherapyRecruitingNCT07365930Report a problem
• A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeRecruitingNCT07284121Report a problem
• TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%RecruitingNCT07279402Report a problem
• Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLCNot yet recruitingNCT07093762Report a problem
• Study of Atezolizumab in Advanced Non-oncogene-addicted NSCLC With PD-L1 ≥50%, Including Longitudinal c-FLIP Assessment in Monocytic MDSCs.Not yet recruitingNCT07051928Report a problem
• HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCCNot yet recruitingNCT07045558Report a problem
• Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung CancerNot yet recruitingNCT07035860Report a problem
• Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingNCT07021911Report a problem
• GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）RecruitingNCT06988592Report a problem
• SIRT and Peri-immunotherapy : a New ConceptNot yet recruitingNCT06971237Report a problem
• Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung CancerRecruitingNCT06926179Report a problem
• Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid BiopsyRecruitingNCT06869239Report a problem
• Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular CarcinomaRecruitingNCT06806579Report a problem
• A Study on the Efficacy of Atezolizumab Combined with ChemotherapyRecruitingNCT06780826Report a problem
• Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)RecruitingNCT06717243Report a problem
• Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular CarcinomaRecruitingNCT06323382Report a problem
• Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma.Not yet recruitingNCT06244446Report a problem
• A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.RecruitingNCT06205732Report a problem
• DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic CholangiocarcinomaRecruitingNCT06194695Report a problem
• Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world StudyNot yet recruitingNCT06024252Report a problem
• A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLCRecruitingNCT05991206Report a problem
• The ImmunoXXL StudyRecruitingNCT05879328Report a problem
• TIP in Patients Affected by Metastatic TNBCRecruitingNCT05831553Report a problem
• Panomic Approach to Immune-Connected Assays in Small Cell Lung CancerRecruitingNCT05797493Report a problem
• Ate-Bev Early Response Prediction Model in Advanced HCCRecruitingNCT05763277Report a problem
• Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT05717738Report a problem
• Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT05713994Report a problem
• Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular CarcinomaRecruitingNCT05573282Report a problem
• Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLCRecruitingNCT05418660Report a problem
• Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical PracticeRecruitingNCT05402059Report a problem
• International Multicentric Study ARON-1RecruitingNCT05287464Report a problem
• Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by ImmunotherapyRecruitingNCT05263830Report a problem
• Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung CancerRecruitingNCT05260606Report a problem
• Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabRecruitingNCT05173298Report a problem
• Montreal Immune-Related Adverse Events (MIRAE) StudyRecruitingNCT05139706Report a problem
• Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational StudyRecruitingNCT04680598Report a problem
• Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin ToxicityRecruitingNCT04631731Phase 1/2Report a problem
• Immunotherapy in Lung Cancer: Treatment After IO Cessation.RecruitingNCT04465942Report a problem
• JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint InhibitorsRecruitingNCT04294771Report a problem
• Microbiome Immunotherapy Toxicity and Response EvaluationRecruitingNCT04107168Report a problem
• A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.CompletedNCT05834348Results postedReport a problem
• Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCCCompletedNCT04862949Results postedReport a problem
• Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in SohagActive, not recruitingNCT07669597Report a problem
• A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsActive, not recruitingNCT07645209Report a problem
• The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort StudyCompletedNCT07639294Report a problem
• Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)Active, not recruitingNCT07204327Report a problem
• Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver CirrhosisCompletedNCT07193316Report a problem
• Body Composition and Inflammatory-Metabolic Indices in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI StudyCompletedNCT07192926Report a problem
• Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung CarcinomaCompletedNCT07111104Report a problem
• Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular CarcinomaCompletedNCT07091942Report a problem
• Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1CompletedNCT07036016Report a problem
• Pathological and Clinical Features of Patients Treated With ATZ+BEV in RomaniaCompletedNCT06903663Report a problem
• HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCCActive, not recruitingNCT06632106Report a problem
• Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-immunotherapy Combination Using Imaging Mass Cytometry (HYPE)Active, not recruitingNCT06558903Report a problem
• A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial ChemoembolizationCompletedNCT06503250Report a problem
• Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)CompletedNCT06416683Report a problem
• Survival Analysis: TACE vs. Combination Therapy in HCCCompletedNCT06261138Report a problem
• Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular CarcinomaCompletedNCT06199297Report a problem
• B7-Family Score in Urothelial CarcinomaCompletedNCT06169904Report a problem
• An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With SurgeryActive, not recruitingNCT06117891Report a problem
• EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance DatabaseCompletedNCT05934214Report a problem
• Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast CancerTerminatedNCT05742269Report a problem
• Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast CancerCompletedNCT05609903Report a problem
• KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIActive, not recruitingNCT05525858Report a problem
• TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompletedNCT05332821Report a problem
• TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCCompletedNCT05332496Report a problem
• Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCCompletedNCT05261438Report a problem
• Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic TherapyCompletedNCT05197504Report a problem
• Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung CancerCompletedNCT05055999Report a problem
• Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung CancerCompletedNCT05055947Report a problem
• Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular CarcinomaTerminatedNCT05044676Report a problem
• Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world StudyCompletedNCT04975932Report a problem
• Atezolizumab Combined With Chemotherapy in Extensive Stage SCLCCompletedNCT04920981Report a problem
• The Prospective Non-randomized Case-control Study From Real-world Lung Cancer PatientsCompletedNCT04909164Report a problem
• Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint InhibitorsCompletedNCT04898751Report a problem
• Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic CancerNo longer availableNCT04869501Report a problem
• The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)CompletedNCT04818983Report a problem
• ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable orStatus unknownNCT04730388Report a problem
• Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLCStatus unknownNCT04663438Report a problem
• Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCCStatus unknownNCT04639284Report a problem
• Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)CompletedNCT04501497Report a problem
• Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 InhibitorsStatus unknownNCT04355806Report a problem
• A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC PatientsCompletedNCT04312308Report a problem
• Immune Related-adverse Events in Patients Receiving Immune Checkpoint InhibitorsStatus unknownNCT04268368Report a problem
• Polish Microbiome MapStatus unknownNCT04169867Report a problem
• A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin AmericaCompletedNCT04158258Report a problem
• AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.Status unknownNCT04145232Report a problem
• BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and DiagnosticsStatus unknownNCT04136470Report a problem
• PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort StudyStatus unknownNCT04115410Report a problem
• Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus ChemotherapyCompletedNCT03911219Report a problem
• Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)CompletedNCT03868046Report a problem

← Atezolizumab